Article
Biological and therapeutic implications of a unique subtype of NPM1 mutated AML.
Nature communications - 16 Feb 2021
Mer Arvind Singh, Heath Emily M, Madani Tonekaboni Seyed Ali, Dogan-Artun Nergiz, Nair Sisira Kadambat, Murison Alex, Garcia-Prat Laura, Shlush Liran, Hurren Rose, Voisin Veronique, Bader Gary D, Nislow Corey, Rantalainen Mattias, Lehmann Soren, Gower Mark, Guidos Cynthia J, Lupien Mathieu, Dick John E, Minden Mark D, Schimmer Aaron D, Haibe-Kains Benjamin
Abstract excerpt
In acute myeloid leukemia (AML), molecular heterogeneity across patients constitutes a major challenge for prognosis and therapy. AML with NPM1 mutation is a distinct genetic entity in the revised World Health Organization classification. However, differing patterns of co-mutation and response to therapy within this group necessitate further stratification. Here we report two distinct subtypes within NPM1 mutated...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.